The role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2089-2099

  Scherma, Maria ^a   Fattore, Liana ^a,b   Castelli, Maria Paola ^a   Fratta, Walter ^a   Fadda, Paola ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

Anorexia nervosa; Binge eating disorder; Bulimia nervosa; CB1 receptors; Eating disorders; Endocannabinoid system; Food intake; Obesity

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ; DOPAMINE; ENDOCANNABINOID; GHRELIN; HORMONE; INSULIN; LEPTIN; MELANIN CONCENTRATING HORMONE; NALOXONE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTRANSMITTER; OXYTOCIN; RIMONABANT; TYROSINE 3 MONOOXYGENASE;

ADDICTION; ANOREXIA NERVOSA; APPETITE; ATTITUDE; BINGE EATING DISORDER; BRAIN REGION; BULIMIA; DIET RESTRICTION; DSM-IV; EATING DISORDER; EMOTIONAL STRESS; FEEDING BEHAVIOR; FOOD INTAKE; HORMONE ACTION; HUMAN; LOSS OF APPETITE; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; REWARD; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM; ANIMAL; EATING DISORDERS; NUCLEUS ACCUMBENS; PHYSIOLOGY;

ANIMALS; EATING DISORDERS; ENDOCANNABINOIDS; FEEDING BEHAVIOR; HUMANS; NUCLEUS ACCUMBENS; OBESITY; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; VENTRAL TEGMENTAL AREA;

EID: 84903729231     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990429     Document Type: Review

References (176)

1. Foltin RW, Brady JV, Fischman MW. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 1986; 25: 577-82.
2. Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988; 11: 1-14.
3. Mattes RD, Engelman K, Shaw LM, Elsohly MA. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994; 49: 187-95.
4. Plasse TF. Clinical use of dronabinol. J Clin Oncol 1991; 9: 2079-80.
5. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999; 143: 315-7.
6. Gómez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-7.
7. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012; 204: 207-29.
8. Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives. J Psychopharmacol 2012; 26: 150-63.
9. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-84.
10. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765-74.
11. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009; 60: 77-84.
12. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.
13. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-6.
14. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
15. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325.
16. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
17. Matsuda LA. Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 1997; 11: 143-66.
18. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010; 160: 467-79.
19. Fride E, Foox A, Rosenberg E, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a CB3 receptor. Eur J Pharmacol 2003; 461: 27-34.
20. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-101.
21. Chávez AE, Chiu CQ, Castillo PE. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 2010; 13: 1511-8.
22. De Petrocellis L, Di Marzo V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 2010; 5: 103-21.
23. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819-24.
24. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
25. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999; 96: 12198-203.
26. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315-48.
27. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006; 29: 225-32.
28. Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol 2008; 154: 369-83.
29. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-9.
30. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27-37.
31. Anderson-Baker WC, McLaughlin CL, Baile CA. Oral and hypothalamic injections of barbiturates, benzodiazepines and cannabinoids and food intake in rats. Pharmacol Biochem Behav 1979; 11: 487-91.
32. Williams CM, Rogers PJ, Kirkham TC. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 1998; 65: 343-6.
33. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000; 392: 147-56.
34. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151-4.
35. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-7.
36. Soria-Gòmez E, Matias I, Rueda-Orozco PE, et al. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 2007; 151: 1109-16.
37. Verty AN, McGregor IS, Mallet PE. Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol. Neuropharmacology 2005; 49: 1101-09.
38. Williams CM, Kirkham TC. Reversal of D9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002; 71: 341-8.
39. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76: 245-50.
40. Scopinho AA, Guimarães FS, Corrêa FM, Resstel LB. Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists. Pharmacol Biochem Behav 2011; 98(2): 268-72.
41. Arnone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997; 132: 104-6.
42. McLaughlin PJ, Winston K, Swezey L, et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003; 14: 583-8.
43. Colombo G, Agabio R, Diaz G. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998; 63: 113-7.
44. Shearman LP, Rosko KM, Fleischer R, et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003; 14: 573-82.
45. Rutkowska M. The effect of AM251, a cannabinoid CB1 receptor antagonist, on food intake in rats. Acta Pol Pharm 2004; 61: 401-3.
46. Carai MA, Colombo G, Maccioni P, Gessa GL. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006; 12: 91-9.
47. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 2009; 156: 1154-66.
48. Wiley JL, Burston JJ, Leggett DC, et al. CB(1) cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005; 145: 293-300.
49. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-95.
50. Anand BK, Brobeck JR. Localization of a" feeding center" in the hypothalamus of the rat, Proc Soc Exp Biol Med 1951; 77: 323-24.
51. Hetherington AW, Ranson SW. Hypothalamic lesions and adiposity in the rat. Anat Rec 1940; 78: 149-72.
52. He W, Lam TK, Obici S, Rossetti L. Molecular disruption of hypothalamic nutrient sensing induces obesity. Nature Neurosci 2006; 9: 227-33.
53. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001; 74: 683-701.
54. Cota D, Marsicano G, Tschöp M, Grubler Y, Flachskamm C, Schubert M. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31.
55. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005; 49: 646-52.
56. Osei-Hyiaman D, Depetrillo M, Harvey-White J, et al. Cocaineand amphetamine related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 2005; 81: 273-82.
57. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004; 92: 757-61.
58. Kola B, Farkas I, Christ-Crain M, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 2008; 3: 1797.
59. Jo YH, Chen YJ, Chua SC Jr, Talmage DA, Role LW. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005; 48: 1055-66.
60. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-5.
61. Poncelet M, Maruani J, Calassi R, Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003; 343: 216-8.
62. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004; 143: 520-3.
63. Verty AN, McFarlane JR, McGregor IS, Mallet PE. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004; 145: 3224-31.
64. Verty AN, McFarlane JR, McGregor IS, Mallet PE. Evidence for aninteraction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 2004; 47: 593-603.
65. Kirkham TC, Williams CM. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 2001; 153: 267-70.
66. Verty AN, Singh ME, McGregor IS, Mallet PE. The cannabinoid receptor antagonist SR141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology 2003; 168: 314-23.
67. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-13.
68. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445-49.
69. Wise RA. Roles for nigrostriatal-not just mesocorticolimbic- dopamine in reward and addiction. Trends Neurosci 2009; 32: 517-24.
70. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol 1989; 40: 191-225.
71. Berridge KC, Ho CY, Richard JM, et al. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res 2010; 1350: 43-64.
72. Horvath TL, Diano S. The floating blueprint of hypothalamic feeding circuits. Nat Rev Neurosci 2004; 5: 662-7.
73. Kelley AE, Baldo BA, Pratt WE, Will MJ. Corticostriatalhypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 2005; 86: 773-95.
74. Dallman MF, Akana SF, Strack AM, et al. Chronic stress-induced effects of corticosterone on brain: direct and indirect. Ann N Y Acad Sci 2004; 1018: 141-50.
75. Macht M, Mueller J. Immediate effects of chocolate on experimentally induced mood states. Appetite 2007; 49: 667-74.
76. Imaizumi M, Takeda M, Sawano S, Fushiki T. Opioidergic contribution to conditioned place preference induced by corn oil in mice. Behav Brain Res 2001; 121: 129-36.
77. Sclafani A, Bodnar RJ, Delamater AR. Pharmacology of food conditioned preferences. Appetite 1998; 31: 406-20.
78. Hajnal A, Smith GP, Norgren R. Oral sucrose stimulation increases accumbens dopamine in the rat. Am J Physiol Regul Integr Comp Physiol 2004; 286: R31-7.
79. Rada P, Avena NM, Hoebel BG. Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell. Neuroscience 2005; 134: 737-44.
80. Liang NC, Hajnal A, Norgren R. Sham feeding corn oil increases accumbens dopamine in the rat. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1236-9.
81. Barzaghi F, Groppetti A, Mantegazza P, Müller EE Reduction of food intake by apomorphine: a pimozide-sensitive effect. J Pharm Pharmacol 1973; 25: 909-11.
82. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995; 83: 1197-209.
83. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 2005; 81: 263-84.
84. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22: 565-72.
85. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-92.
86. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 2002; 99: 8384-88.
87. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 2004; 24: 53-62.
88. Lupica CR, Riegel AC. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 2005; 48: 1105-16.
89. Brown JE, Kassouny M, Cross JK. Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of delta-9-tetrahydrocannabinol. Behav Biol 1977; 20: 104-10.
90. Koch JE, Matthews SM. Delta9-tetrahydrocannabinol stimulates palatable food intake in Lewis rats: effects of peripheral and central administration. Nutr Neurosci 2001; 4: 179-87.
91. Miller CC, Murray TF, Freeman KG, Edwards GL. Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain. Physiol Behav 2004; 80: 611-6.
92. Dipatrizio NV, Simansky KJ. Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. Am J Physiol Regul Integr Comp Physiol 2008; 295: 1409-14.
93. Simiand J, Keane M, Keane PE, Soubrie P. SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998; 9: 179-81.
94. Chaperon F, Soubrié P, Puech AJ, Thiébot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998; 135: 324-32.
95. South T, Deng C, Huang X-F. AM 251 and [beta]-Funaltrexamine reduce fat intake in a fat-preferring strain of mouse. Behav Brain Res 2007; 181: 153-7.
96. Mathes CM, Ferrara M, Rowland NE. Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. Am J Physiol Regul Integr Comparat Physiol 2008; 295: R67-R75.
97. Gallate JE, Saharov T, Mallet PE, McGregor IS. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 1999; 370: 233-40.
98. Gallate JE, McGregor IS. The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716 Psychopharmacology 1999; 142: 302-8.
99. Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems Neuropsychopharmacology 2005; 30: 2035-45.
100. Mahler SV, Smith KS, Berridge KC. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward Neuropsychopharmacology 2007; 32: 2267-78.
101. Foltin RW, Haney M. Effects of the cannabinoid antagonist SR141716 (Rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates. Pharmacol Biochem Behav 2007; 86: 766-73.
102. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision (DSM-IV-TR). Washington: American Psychiatric Association, 2000.
103. Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008; 94: 121-35.
104. Kaye WH, Bailer UF. Understanding the neural circuitry of appetitive regulation in eating disorders. Biol Psychiatry 2011; 70: 704-5.
105. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psych 2007; 61: 348-58.
106. Fairburn CG, Cooper Z. Thinking afresh about classification of eating disorders. Int J Eat Disord 2007; 40: S107-10.
107. Attia E. Anorexia nervosa: current status and future directions. Annu Rev Med 2010; 61: 425-35.
108. Mattar L, Huas C, Duclos J, Apfel A, Godart N. Relationship between malnutrition and depression or anxiety in anorexia nervosa: a critical review of the literature. J Affect Disord 2011; 132: 311-8.
109. Van den Eynde F, Guillaume S, Broadbent H, et al. Neurocognition in bulimic eating disorders: a systematic review. Acta Psychiatr Scand 2011; 124: 120-40.
110. Brewerton TD, Lydiard RB, Herzog DB, Brotman AW, O'Neil PM, Ballenger JC. Comorbidity of axis I psychiatric disorders In bulimia nervosa. J Clin Psychiatry 1995; 56: 77-80.
111. Johnson JG, Spitzer RL, Williams JB. Health problems, impairment and illnesses associated with bulimia nervosa and binge eating disorder among primary care and obstetric gynaecology patients. Psychol Med 2001; 31: 1455-66.
112. Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord 2009; 42: 228-34.
113. Wiederman MW, Pryor T. Substance use among women with eating disorders. Int J Eat Disord 1996; 20: 163-8.
114. Davis C, Carter JC. Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite 2009; 53: 1-8.
115. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-55.
116. Hyde R Europe battles with obesity. Lancet 2008; 371: 2160-1.
117. González Jiménez E. Obesity: etiologic and pathophysiological analysis. Endocrinol Nutr 2012 May 21. [Epub ahead of print].
118. Wonderlich SA, Mitchell JE.Eating disorders and comorbidity: empirical, conceptual, and clinical implications. Psychopharmacol Bull 1997; 33: 381-90.
119. Ross CE. Overweight and depression. J Health Soc Behav 1994; 35: 63-79.
120. Volkow ND, O'Brien CP. Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry 2007; 164: 708-10.
121. Marcus MD, Wildes JE. Obesity: is it a mental disorder? Int J Eat Disord 2009; 42: 739-53.
122. Moreno C, Tandon R. Should overeating and obesity be classified as an addictive disorder in DSM-5? Curr Pharm Des 2011; 17: 1128-31.
123. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 2005, 29: 755-9.
124. Monteleone P, Tortorella A, Martiadis V, Di Filippo C, Canestrelli B, Maj M. The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women. Psychoneuroendocrinology 2008; 33: 546-50.
125. Siegfried Z, Kanyas K, Latzer Y, et al. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am J Med Genet B Neuropsychiatr Genet 2004; 125: 126-30.
126. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005; 30: 1216-21.
127. van der Staay FJ, Arndt SS, Nordquist RE. Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct 2009; 25; 5: 11.
128. Casper, R.C., Sullivan, E.L., Tecott, L. Relevance of animal models to human eating disorders and obesity. Psychopharmacology 2008; 199: 313-29.
129. Oldershaw A, Hambrook D, Stahl D, Tchanturia K, Treasure J, Schmidt U. The socio-emotional processing stream in anorexia nervosa. Neurosci Biobehav Rev 2011; 35: 970-88.
130. Routtenberg A, Kuznesof AW. Self-starvation of rats living in activity wheels on a restricted feeding schedule. J Comp Physiol Psychol 1967; 64: 414-21.
131. Pirke KM, Broocks A, Wilckens T, Marquard R, Schweiger U. Starvation-induced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. Neurosci Biobehav Rev 1993; 17: 287-94.
132. Wang SW. Effects of restraint stress and serotonin on macronutrient selection: a rat model of stress-induced anorexia. Eat Weight Disord 2002; 7: 23-31.
133. Johansen JE, Fetissov S, Fischer H, Arvidsson S, Hökfelt T, Schalling M. Approaches to anorexia in rodents: focus on the anx/anx mouse. Eur J Pharmacol 2003; 480: 171-6.
134. Casper, R.C., 1998. Biology of Eating Disorders, second ed. American Psychiatric Press, Washington, DC.
135. Hagan MM, Moss DE. An animal model of bulimia nervosa: opioid sensitivity to fasting episodes. Pharmacol Biochem Behav 1991; 39: 421-2.
136. Avena NM, Bocarsly ME. Dysregulation of brain reward systems in eating disorders: Neurochemical information from animal models of binge eating, bulimia nervosa, and anorexia nervosa. Neuropharmacology 2012; 63: 87-96.
137. Hagan MM, Wauford PK, Chandler PC, Jarrett LA, Rybak RJ, Blackburn K. A new animal model of binge-eating: key synergistic role of past caloric restriction and stress. Physiol Behav 2002; 77: 45-54.
138. Corwin RL, Buda-Levin A. Behavioral models of binge-type eating. Physiol Behav 2004; 82: 123-30.
139. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
140. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-5.
141. Kennedy AJ,. Ellacott KLJ, King VL, A.H. Hasty. Mouse models of the metabolic syndrome Dis Model Mech 2010; 3: 156-66.
142. Vickers SP, Jackson HC, Cheetham SC. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 2011; 164: 1248-62.
143. Kim SF. Animal models of eating disorders. Neuroscience 2012; 211: 2-12.
144. Lewis DY, Brett RR. Activity-based anorexia in C57/BL6 mice: effects of the phytocannabinoid, Delta9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2. Eur Neuropsychopharmacol 2010; 20: 622-31.
145. Verty AN, Evetts MJ, Crouch GJ, McGregor IS, Stefanidis A, Oldfield BJ. The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology 2011; 36: 1349-58.
146. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 2002; 135: 564-78.
147. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology 2002; 163: 111-7.
148. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmcol Exp Ther 2006; 318: 304-11.
149. Corwin RL, Avena NM, Boggiano MM. Feeding and reward: perspectives from three rat models of binge eating. Physiol Behav 2011; 104: 87-97.
150. Scherma M, Fattore L, Satta V, et al. Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behavior in female rats. Br J Pharmacol. 2012 Oct 16. doi: 10.1111/bph.12014.
151. Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacol Biochem Behav 1996; 53: 221-6.
152. Bassareo V, Di Chiara G. Modulation of feeding-induced activation of mesolimbic dopamine transmission by appetitive stimuli and its relation to motivational state. Eur J Neurosci 1999; 11: 4389-97.
153. Wise RA, Newton P, Leeb K, Burnette B, Pocock D, Justice JB. Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology 1995; 120: 10-20.
154. Rada P, Avena NM, Hoebel BG. Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell. Neuroscience 2005; 134: 737-44.
155. Liang NC, Hajnal A, Norgren R. Sham feeding corn oil increases accumbens dopamine in the rat. Am J Physiol Regul Integr Comp Physiol 2006; 291: 1236-9.
156. Melis MR, Succu S, Mascia MS, et al. The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide. Neuropharmacology 2007; 50: 219-28.
157. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennettt GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 2003; 167: 103-11.
158. Ravinet-Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to dietinduced obesity and enhanced insulin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-8.
159. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Anti-obesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003; 462: 125-32.
160. Carr TP, Jesch ED, Brown AW. Endocannabinoids, metabolic regulation, and the role of diet. Nutr Res 2008; 28: 641-50.
161. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G. Downregulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002; 952: 232-8.
162. South T, Huang XF. Temporal and site-specific brain alterations in CB1 receptor binding in high fat diet-induced obesity in C57Bl/6 mice. J Neuroendocrinol 2008; 20: 1288-94.
163. Timofeeva E, Baraboi ED, Poulin AM, Richard D. Palatable highenergy diet decreases the expression of cannabinoid type 1 receptor messenger RNA in specific brain regions in the rat. J Neuroendocrinol 2009; 21: 982-92.
164. Bello NT, Coughlin JW, Redgrave GW, Ladenheim EE, Moran TH, Guarda AS. Dietary conditions and highly palatable food access alter rat cannabinoid receptor expression and binding density. Physiol Behav 2012; 105: 720-6.
165. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro D. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 1994; 5: 2493-6.
166. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res. 1997; 44: 191-7.
167. Jackson CW, Cates M, Lorenz R. Pharmacotherapy of eating disorders. Nutr Clin Pract 2010; 25: 143-59.
168. Monteleone P. New frontiers in endocrinology of eating disorders. Curr Top Behav Neurosci 2011; 6: 189-208.
169. Di Marzo V, Després JP. CB1 antagonists for obesity--what lessons have we learned from rimonabant? Nat Rev Endocrinol 2009; 5: 633-8.
170. Kirilly E, Gonda X, Bagdy G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol 2012; 20: 41-60.
171. Kenakin T. Allosteric modulators: the new generation of receptor antagonist. Mol Interv 2004; 4: 222-9.
172. Giraldo J, Serra J, Roche D, Rovira X. Assessing receptor affinity for inverse agonists: Schild and Cheng-Prusoff methods revisited. Curr Drug Targets 2007; 8: 197-202.
173. Järbe TU, LeMay BJ, Olszewska T, Vemuri VK, Wood JT, Makriyannis A. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav 2008; 91: 84-90.
174. Gross H, Ebert MH, Faden VB, et al. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 1983; 3: 165-71
175. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndromeassociated anorexia. J Pain Symptom Manage 1997; 14: 7-14.
176. Beal JE, Olson R, Laubenstien L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89-97.